WALTHAM, Mass.– Trinity Life Sciences, a leader in global life sciences commercialization solutions, introduces a Cell & Gene Therapy (C>) Center of Excellence (COE) that supports life sciences companies in successfully commercializing a C> asset. The unique challenges and opportunities in commercializing C> are markedly different from traditional one-size-fits-all products, requiring innovation and a change in the traditional commercial model.
To enable true commercialization optimization in the C> space, there are several areas with C> nuances that need to be considered:
- Operational Model Efficiencies
- Specialized Manufacturing & Supply Chain Logistics
- Market Access Complexity
- Unique Go-To-Market Strategies
- Patient Centricity
- Life Cycle Management
Trinity’s C> COE provides global partnership to life sciences companies and other service providers in the value chain through advisory services powered by a dedicated team of experts with extensive C> commercialization and disease area expertise. Clients are able to leverage expert support and analytical depth, no matter where they are in the commercialization journey. Advisory project examples include:
– Comprehensive situation analysis as a foundation for a gene therapy
– Launch management activities in preparation to commercialize a cell therapy product
– Opportunity evaluation and business development decision support for gene therapies
– Understanding of current market dynamics, potential peak share and value drivers for a novel product
– Modeling of potential Health Care Professionals (HCP) uptake, pricing opportunities and size of the eligible populations for a gene therapy forecast
– And much more
“Trinity is patient first—and every challenge in C> commercialization has the added impetus of patients waiting for life-changing therapies,” explains Herman Sanchez, Chief Business Officer at Trinity Life Sciences. “Understanding and resolving those problems have become table stakes with C> assets. As these treatments may be curative or first on the market, that work is especially meaningful and impactful.”
“After years of experiencing industry challenges firsthand while commercializing gene therapies, I understand the value of strategic partners who are experienced in C> and have supported manufacturers along the challenges commercialization presents,” explained Keren Shani, Executive Director and Head of Cell & Gene Therapy at Trinity Life Sciences. “Trinity launched the C> COE to support clients in a uniquely cross-functional way, so that we can share learnings from our depth of exposure and breadth of experience across client organizations and throughout the lifecycle.”
A new white paper, Empowering Cancer Immunotherapy: Unleashing the Potential of NK Cell Therapies in Oncology, delivers an overarching assessment of the Natural Killer (NK) cell therapy space with a background on NK-based technology, current clinical development—and ultimately, the value proposition NK cell therapies hold in order to equip readers with the necessary knowledge to drive informed decision-making and potential investment in the space.
An on-demand webinar, Gene Therapy Uptake: The Elephant in the Room, evaluates the factors that are unique to forecasting gene therapy markets and discusses what companies need to know to maximize their revenue potential. Among other topics, viewers will hear potential pricing strategies to consider—as well as key market drivers and product factors contributing to gene therapy opportunity.
